Impact of Hepatitis C Virus (HCV) Genotypes on Quantification of HCV RNA in Serum by COBAS AmpliPrep/COBAS TaqMan HCV Test, Abbott Antiretroviral Therapy HCV RealTime Assay, and VERSANT HCV RNA Assay
Édouard Tuaillon(Hôpital Lapeyronie), Anne‐Marie Mondain(Hôpital Lapeyronie), Laure Ottomani(Hôpital Lapeyronie), Laurent Roudière(Hôpital Lapeyronie), Pascal Perney(Institut de Recherche en Santé Digestive), Marie‐Christine Picot(Hôpital Arnaud de Villeneuve), Fabienne Séguret(Hôpital Arnaud de Villeneuve), F Blanc(Institut de Recherche en Santé Digestive), Dominique Larrey(Hôpital Saint Eloi), Philippe Van de Perre(Hôpital Lapeyronie), J Ducos(Hôpital Lapeyronie)
Cited by 24Open Access
Abstract
The VERSANT HCV RNA 3.0 (bDNA), COBAS AmpliPrep/COBAS TaqMan HCV, and Abbott ART HCV RealTime assays were compared for hepatitis C virus RNA quantification in 158 clinical specimens (genotypes 1 to 5). RNA values differed significantly between methods (P < 0.0001), and mean titer differences ranged from 0.01 to 0.50 log(10) IU/ml depending on the genotypes.
Related Papers
No related papers found
Powered by citation graph analysis